Literature DB >> 11713248

The kinase-null EphB6 receptor undergoes transphosphorylation in a complex with EphB1.

Andrew Freywald1, Nigel Sharfe, Chaim M Roifman.   

Abstract

Uniquely for the Eph family of receptor tyrosine kinases, the EphB6 receptor is catalytically inactive due to the alteration of several critical residues in its kinase domain. This has cast doubt upon its ability to participate in cytoplasmic signaling events. We show here that despite its lack of kinase activity, EphB6 undergoes inducible tyrosine phosphorylation upon stimulation with the Eph-B receptor subfamily ligand ephrin-B1. We also demonstrate, for the first time, evidence of cross-talk between Eph receptors. Overexpression of a catalytically active member of the Eph-B subfamily, EphB1, resulted in increased EphB6 phosphorylation. EphB1-induced EphB6 phosphorylation was ligand-dependent and required the functional catalytic activity of EphB1. EphB1 not only transphosphorylated EphB6, but together they also formed a stable hetero-complex. In addition, we identify the proto-oncogene c-Cbl as an EphB6-binding protein. Although EphB6-Cbl association appeared to be constitutive, Cbl required a functional phosphotyrosine binding domain in order to bind the receptor, whereas its RING finger motif ubiquitin-transfer domain was not necessary. Our findings demonstrate that EphB6 is an actively signaling receptor that undergoes transphosphorylation upon ligand binding and that can initiate specific cytoplasmic signaling events.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11713248     DOI: 10.1074/jbc.M108011200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Mistargeting hippocampal axons by expression of a truncated Eph receptor.

Authors:  Yong Yue; Zhi-Yong Chen; Nick W Gale; Jan Blair-Flynn; Tian-Jing Hu; Xin Yue; Margaret Cooper; David P Crockett; George D Yancopoulos; Lino Tessarollo; Renping Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-17       Impact factor: 11.205

2.  EphB6-null mutation results in compromised T cell function.

Authors:  Hongyu Luo; Guang Yu; Johanne Tremblay; Jiangping Wu
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 3.  Bidirectional ephrin/Eph signaling in synaptic functions.

Authors:  Jason Aoto; Lu Chen
Journal:  Brain Res       Date:  2006-12-12       Impact factor: 3.252

4.  Quantitative phosphotyrosine proteomics of EphB2 signaling by stable isotope labeling with amino acids in cell culture (SILAC).

Authors:  Guoan Zhang; Daniel S Spellman; Edward Y Skolnik; Thomas A Neubert
Journal:  J Proteome Res       Date:  2006-03       Impact factor: 4.466

Review 5.  Getting direction(s): The Eph/ephrin signaling system in cell positioning.

Authors:  Terren K Niethamer; Jeffrey O Bush
Journal:  Dev Biol       Date:  2018-01-31       Impact factor: 3.582

6.  The RTK Interactome: Overview and Perspective on RTK Heterointeractions.

Authors:  Michael D Paul; Kalina Hristova
Journal:  Chem Rev       Date:  2018-12-27       Impact factor: 60.622

Review 7.  Eph-dependent cell-cell adhesion and segregation in development and cancer.

Authors:  Eva Nievergall; Martin Lackmann; Peter W Janes
Journal:  Cell Mol Life Sci       Date:  2011-12-28       Impact factor: 9.261

Review 8.  Eph/ephrin recognition and the role of Eph/ephrin clusters in signaling initiation.

Authors:  Dimitar B Nikolov; Kai Xu; Juha P Himanen
Journal:  Biochim Biophys Acta       Date:  2013-04-26

9.  Ephrin-B reverse signaling controls septation events at the embryonic midline through separate tyrosine phosphorylation-independent signaling avenues.

Authors:  Christopher Dravis; Mark Henkemeyer
Journal:  Dev Biol       Date:  2011-04-22       Impact factor: 3.582

10.  High expression of EphB6 protein in tongue squamous cell carcinoma is associated with a poor outcome.

Authors:  Yingchun Dong; Jicheng Pan; Yanhong Ni; Xiaofeng Huang; Xiao Chen; Jiandong Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.